Breo Ellipta (GlaxoSmithKline/Innoviva) Drug Outlook to 2026: A Combination of Fluticasone Furoate & Vilanterol Indicated for the Treatment of Asthma & COPD – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Breo Ellipta” report has been added to ResearchAndMarkets.com’s offering.

Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Fluticasone furoate is an inhaled corticosteroid that activates the glucocorticoid response element and inhibits pro-inflammatory transcription factors such as NFKB, and antigen-induced lung eosinophilia, thereby suppressing inflammation. Vilanterol is a long-acting beta 2 agonist that stimulates intracellular adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate to cyclic-3′,5′-adenosine monophosphate (AMP). Increased levels of cyclic AMP result in the relaxation of bronchial smooth muscles and inhibition of the release of mediators of immediate hypersensitivity from mast cells.

Breo received US approval for use in COPD in May 2013 and launched as the first once-daily ICS/LABA in the COPD market in October 2013. Breo received EU approval for use in COPD in November 2013 (under the brand name Relvar), and became available in the UK and Germany in January 2014. In February 2016, GlaxoSmithKline filed Breo for the treatment of COPD in Japan. It was subsequently approved in December 2016 and launched early 2017.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Breo Ellipta: Chronic obstructive pulmonary disease (COPD)
  4. Breo Ellipta: Asthma

List of Figures

Figure 1: Breo for COPD – SWOT analysis

Figure 2: The authors drug assessment summary of Breo for COPD

Figure 3: The authors drug assessment summary of Breo for COPD

Figure 4: Breo sales for COPD across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Breo Ellipta for asthma – SWOT analysis

Figure 6: The authors drug assessment summary of Breo Ellipta in asthma

Figure 7: The authors drug assessment summary of Breo Ellipta in asthma

Figure 8: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Breo drug profile

Table 2: Breo Phase III data in COPD

Table 3: Breo Phase III trials in COPD

Table 4: Breo sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 5: Breo Ellipta drug profile

Table 6: Breo Ellipta pivotal trial data in asthma

Table 7: Breo Ellipta late-phase trial data in asthma

Table 8: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/50g72i

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Respiratory Drugs, Asthma Drugs